Payment overview · 2025
General Payments
$1,597.46
14 reported records · 6 companies
Healthcare provider profile · identity verified
Luzviminda T. Montecillo, MD
Allopathic & Osteopathic Physicians|Internal Medicine · INGLEWOOD, CA · NPI 1447348149
Verified facts
What the public records show
CMS Open Payments records show Luzviminda T. Montecillo, MD received $1,597.46 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 28.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $458.50 | 28.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $425.99 | 26.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $364.45 | 22.8% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $158.40 | 9.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $147.62 | 9.2% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,554.96 | 13 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $364.45 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $306.35 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $240.66 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $217.84 | 2 | 2025 |
Source payment records
|
|||||
| NICO BRAINPATH Normalized: nico brainpath |
Device | Stryker Corporation | $158.40 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $147.62 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $119.64 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.45 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1282 | 314 |
| Amlodipine Besylate | Amlodipine Besylate | 797 | 191 |
| Metformin Hcl | Metformin Hcl | 554 | 133 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 419 | 60 |
| Losartan Potassium | Losartan Potassium | 412 | 119 |
| Hydrochlorothiazide | Hydrochlorothiazide | 302 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 51 |
| Lisinopril | Lisinopril | 282 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 267 | 65 |
| Gabapentin | Gabapentin | 232 | 62 |
| Quetiapine Fumarate | Quetiapine Fumarate | 223 | 23 |
| Carvedilol | Carvedilol | 209 | 37 |
| Furosemide | Furosemide | 194 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 177 | 40 |
| Eliquis | Apixaban | 156 | 15 |
| Lactulose | Lactulose | 155 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 45 |
| Trulicity | Dulaglutide | 136 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 27 |
| Potassium Chloride | Potassium Chloride | 129 | 43 |
| Omeprazole | Omeprazole | 128 | 28 |
| Naproxen | Naproxen | 127 | 33 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 121 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 24 |
| Linzess | Linaclotide | 117 | 41 |
| Azithromycin | Azithromycin | 106 | 82 |
| Famotidine | Famotidine | 106 | 17 |
| Celecoxib | Celecoxib | 105 | 21 |
| Benazepril Hcl | Benazepril Hcl | 103 | 21 |
| Memantine Hcl | Memantine Hcl | 93 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 32 |
| Divalproex Sodium | Divalproex Sodium | 90 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 88 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 26 |
| Januvia | Sitagliptin Phosphate | 83 | 17 |
| Ozempic | Semaglutide | 79 | 24 |
| Valsartan | Valsartan | 79 | 12 |
| Alendronate Sodium | Alendronate Sodium | 78 | 21 |
| Simvastatin | Simvastatin | 76 | 15 |
| Meloxicam | Meloxicam | 75 | 20 |
| Mirtazapine | Mirtazapine | 74 | 13 |
| Latanoprost | Latanoprost | 73 | 11 |
| Risperidone | Risperidone | 73 | suppressed |
| Humalog | Insulin Lispro | 72 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 37 |
| Methimazole | Methimazole | 70 | 22 |
| Donepezil Hcl | Donepezil Hcl | 69 | 11 |
| Atenolol | Atenolol | 67 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 15 |
| Xarelto | Rivaroxaban | 66 | suppressed |
| Jardiance | Empagliflozin | 61 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 19 |
| Allopurinol | Allopurinol | 57 | 13 |
| Lovastatin | Lovastatin | 56 | 14 |
| Tramadol Hcl | Tramadol Hcl | 53 | 22 |
| Spironolactone | Spironolactone | 52 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Finasteride | Finasteride | 49 | suppressed |
| Tradjenta | Linagliptin | 48 | 12 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 11 |
| Cephalexin | Cephalexin | 44 | 42 |
| Nifedipine Er | Nifedipine | 43 | 12 |
| Lumigan | Bimatoprost | 41 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 32 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 21 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 38 | 17 |
| Brilinta | Ticagrelor | 37 | suppressed |
| Humulin R | Insulin Regular, Human | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 35 | 32 |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 15 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 28 |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 15 |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 26 |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 29 | suppressed |
| Letrozole | Letrozole | 27 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Novolin R | Insulin Regular, Human | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Klor-Con 8 | Potassium Chloride | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Haloperidol | Haloperidol | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Brinzolamide | Brinzolamide | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 15 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | 12 |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | 11 |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | 11 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | 13 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Olanzapine Odt | Olanzapine | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,597.46 · 14 records | Novo Nordisk Inc | AFREZZA, AIRSUPRA, BREZTRI, EVENITY, FARAPULSE, FARXIGA, NICO BRAINPATH, Ozempic, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error